15159-40-7

Basic information

• Product Name: 4-Morpholinecarbonyl chloride
• Synonyms: 4-Morpholinecarbonyl;4-Chlorocarbonylmorpholine Morpholinocarbonyl Chloride;MORPHOLINE-4-CARBONYL CHLORIDE;MORPHOLIN-4-YLCARBONYL CHLORIDE;MORPHOLINOCARBONYL CHLORIDE;4-MORPHOLINE CARBONIC ACID CHLORIDE;4-MORPHOLINECARBONYL CHLORIDE;4-MORPHOLINYLCARBONYL CHLORIDE
• CAS NO: 15159-40-7
• Molecular Formula: C₅H₈ClNO₂
• Molecular Weight: 149.58
• EINECS: 239-213-0
• Product Categories: Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Morpholines/Thiomorpholines;ACIDHALIDE;Phosgene Derivatives;Building Blocks;Heterocyclic Building Blocks;Morpholines
• Mol File: 15159-40-7.mol

Chemical Properties

• Boiling Point: 137-138 °C33 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.282 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0418mmHg at 25°C
• Refractive Index: n20/D 1.498(lit.)
• Storage Temp.: Store below +30°C.
• PKA: -2.16±0.20(Predicted)
• BRN: 116257
• CAS DataBase Reference: 4-Morpholinecarbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Morpholinecarbonyl chloride(15159-40-7)
• EPA Substance Registry System: 4-Morpholinecarbonyl chloride(15159-40-7)

Safety Data

• Hazard Codes: Xn
• Statements: 14-36/38-40
• Safety Statements: 26-30-36-38
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• F: 10-21
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 15159-40-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 15159-40-7 differently. You can refer to the following data:
1. Photographic intermediate
2. 4-Morpholinecarbonyl chloride may be used in the preparation of a versatile fluorogenic label for biomolecular imaging. It may be used in the synthesis of:morpholine-4-carboxylic acid [4-(2,4-dimethylphenyl)thiazol-2-yl]amidemorpholine-4-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide2-isopropyl-6-methylpyrimidin-4-yl morpholine-4-carboxylate

General Description

4-Morpholinecarbonyl chloride is a photographic intermediate. Rates of solvolysis of 4-morpholinecarbonyl chloride with N-alkyl group in aqueous binary solvents of acetone, ethanol, methanol, methanol-d, 2,2,2-trifluoroethanol, pure water and D2O has been determined. Preparation of 4-morpholinecarbonyl chloride has been reported.

InChI:InChI=1/C5H8ClNO2/c6-5(8)7-1-3-9-4-2-7/h1-4H2

Upstream product

• 110-91-8 morpholine 
• 75-44-5 phosgene 
• 10316-00-4 4-benzyl-morpholine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 301840-93-7 PdCl(CONCH₂CH₂OCH₂CH₂)(2,2'-dipyridine) 
• 7553-56-2 iodine 
• 301840-94-8 PdCl(CONCH₂CH₂OCH₂CH₂)(1,10-phenanthroline) 
• 128-09-6 N-chloro-succinimide 
• 7782-50-5 chlorine 
• 301840-96-0 Pd(CONCH₂CH₂OCH₂CH₂)2(2,2'-dipyridine) 
• 140-89-6 potassium ethyl xanthogenate 
• 1199-46-8 2-amino-4-tert-butylphenol 
• 2757-23-5 chloro(chlorosulfanyl)methanone 
• 50881-96-4 morpholine-4-carboxylic acid 

Downstream Products

• 121975-53-9 N,N'-bis-(4-nitro-phenyl)-N,N'-ethanediyl-bis-morpholine-4-carboxamide 
• 69630-20-2 4-(phenyloxycarbonyl)morpholine 
• 28142-21-4 morpholine-4-carboxylic acid 4-phenyl-cyclohexylamide 
• 25762-12-3 6-morpholin-4-yl-2,3-diphenyl-2,3-dihydro-[1,3,5]thiadiazin-4-one 
• 31982-33-9 morpholine-4-carboxylic acid 3,4,6-trichloro-2-iodo-phenyl ester 
• 31982-32-8 morpholine-4-carboxylic acid 2-bromo-3,4,6-trichloro-phenyl ester 
• 31982-31-7 morpholine-4-carboxylic acid 3,4,6-trichloro-2-nitro-phenyl ester 
• 34144-41-7 10,11-dihydro-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one O-(morpholine-4-carbonyl)-oxime 
• 25761-92-6 N-Morpholinoformyl-N'-phenyl-thioharnstoff 
• 13606-73-0 morpholine-4-carboxylic acid 3-methyl-anilide 
• 104017-77-8 Morpholine-4-carboxylic acid N'-(3,5-bis-trifluoromethyl-phenyl)-hydrazide 
• 116129-81-8 (4-morpholinylcarbonyl)-β-phenylserine methyl ester 
• 73280-63-4 (Morpholinocarbonyl)phenyl-thiocarbamidsaeure-O-methylester 
• 126089-92-7 (morpholin-4-ylcarbonyl)-Thr-D-Trp(CHO)-Phe-NMeBzl 

Relevant articles and documents

Dual inhibitors of Interleukin-6 and acetylcholinesterase for treatment of Alzheimer's disease: Design, docking, synthesis and biological evaluation

Multitarget compounds intercept two or more functionally complementary pathways simultaneously, and are therefore considered to have potential in effectively treating complex multifactorial diseases like Alzheimer's disease (AD). In the present study, novel molecules are designed by coupling a chromone and a N,N-disubstituted carbamoyl amine as pharmacophore for interleukin-6 (IL-6) and acetylcholinesterase (AChE) inhibition, respectively. Four series (Y1–Y4) of 40 compounds are designed by using alkyl linkers of different lengths (1–4 carbon atoms) for the coupling of the two selected pharmacophore. Docking of all designed compounds in AChE leads to the identification of twelve best fit compounds (Docking score >8.3). The data suggests that a 1- or 2-carbon atom linker is the most conducive to orient the pharmacophore for optimum binding with AChE active site. The predicted ADME properties of the 12 selected compounds suggest that these can cross the blood brain barrier (BBB) with good oral bioavailability. These compounds are synthesised and evaluated for anti-AChE activity. Five compounds, showing >45% inhibition of AChE, are further evaluated for IL-6 inhibitory activity. Compound Y1f is found to be the most potent inhibitor of both AChE and IL-6 (IC50 0.7 and 0.8 ?μM, respectively). It suggests that a chromone moiety connected to a piperidine ring through a 1-carbon atom linker may provide a useful template to medical chemists for the development of new chemical entities effective against AD.

Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application

The invention relates to a cannabidiol carbamate compound, a medicinal preparation, a preparation method and application, and belongs to the field of compounds for treating and preventing diseases related to aging, Alzheimer's disease and Parkinson's disease. The compound has a structure shown as a formula I or a pharmaceutically acceptable salt of the structure shown as the formula I. The compound has good butyrylcholine esterase resisting activity, shows good application prospect in treatment of Alzheimer's disease, and shows good application potential.

Novel cannabidiol?carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease

Cannabidiol (CBD) and rivastigmine have been launched as drugs for treating dementia and cholinesterases (ChEs) are ideal drug targets. This study focused on developing novel ChE inhibitors as drug leads against dementia through molecular modeling and fragment reassembly approaches. A potent carbamate fragment binding to active site gorge of BuChE was found via a docking-based structural splicing approach, thus, 17 novel compounds were designed by structural reassembly. Compound C16 was identified as a highly selective potent BuChE inhibitor (IC50 = 5.3 nM, SI > 4000), superior to CBD (IC50 = 0.67 μM). C16 possessed BBB penetrating ability, benign safety, neuroprotection, antioxidant and pseudo-irreversible BuChE inhibition (Kd = 13 nM, k2 = 0.26 min?1), showing good drug-like properties. In vivo studies confirmed that C16 significantly ameliorated the scopolamine-induced cognition impairment, almost entirely recovered the Aβ1?42 (icv)-impaired cognitive function to the normal level, showed better behavioral performance than donepezil and good anti-amyloidogenic effect. Hence, the potential BuChE inhibitor C16 can be developed as a promising disease-modifying treatment of AD.

LOX ENZYME INHIBITING METHODS AND COMPOSITIONS

This invention relates to compounds, pharmaceutical compositions and their use for treating fibrotic disorders, proliferative disorders, cardiovascular diseases, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, or neurological and neuropsychiatric conditions. One particular aspect of the inventions relates to inhibitors of the family of lysyl oxidase enzymes and their use as therapeutics for fibrotic disorders.

Structure–activity relationships (SARs) of α- ketothioamides as inhibitors of phosphoglycerate dehydrogenase (PHGDH)

For many years now, targeting deregulation within cancer cells’ metabolism has appeared as a promising strategy for the development of more specific and efficient cancer treatments. Recently, numerous reports highlighted the crucial role of the serine synthetic pathway, and particularly of the phosphoglycerate dehydrogenase (PHGDH), the first enzyme of the pathway, to sustain cancer progression. Yet, because of very weak potencies usually in cell-based settings, the inhibitors reported so far failed to lay ground on the potential of this approach. In this paper, we report a structure–activity relationship study of a series of α-ketothioamides that we have recently identified. Interestingly, this study led to a deeper understanding of the structure–activity relationship (SAR) in this series and to the identification of new PHGDH inhibitors. The activity of the more potent compounds was confirmed by cellular thermal shift assays and in cell-based experiments. We hope that this research will eventually provide a new entry point, based on this promising chemical scaffold, for the development of therapeutic agents targeting PHGDH.

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

Synthesis of Piperidine Derivatives by Rhodium- Catalyzed Tandem Reaction of N-Sulfonyl-1,2,3-Triazole and Vinyl Ether

A chemoselective tandem reaction of 4-acyloxymethylene-1-sulfonyl-1,2,3-triazole and vinyl ether was reported, producing polysubstituted piperidine derivatives in up to 96% yield. The key intermediate N-sulfonyl 1-azadiene generated by migration of the OAc group to the α-imino rhodium carbene was isolated and a plausible mechanism was proposed. Several related ring systems were constructed from the highly functionalized products. (Figure presented.).

Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease

A series of 4'-aminochalcone-revastigmine hybrids were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease. The results showed that most of these compounds exhibited good multifunctional activities. In particular, compound 6c displayed the best inhibitory potency on acetylcholinesterase (IC50= 4.91 μM), and significant antioxidative activity with a value 2.83-fold of Trolox. The kinetic analysis of AChE inhibition revealed that 6c showed mixed-type inhibition, binding simultaneously to the catalytic active site and peripheral anionic site of AChE. In addition, 6c inhibited self-induced Aβ1-42aggregation and Cu2+-induced Aβ1-42aggregation by 89.5% and 79.7% at 25 μM respectively, as well as acted as a selective monoamine oxidase B inhibitor (IC50= 0.29 μM) and a selective biometal chelator. Furthermore, 6c could cross the blood-brain barrier in vitro. Based on these results, Compound 6c could be considered as a very promising lead compound for Alzheimer's disease.

Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities

A series of 3-carbamate and 29-ester celastrol derivatives (compounds 1–26) were designed and synthesized. These analogues were evaluated for their cytotoxic activities against several cancer cell lines. Cytotoxicity data revealed that the properties of substituents and substitution position had important influence on cytotoxic activity. Modification of C-3 hydroxyl with size-limited groups did not reduce the activity obviously. The introduction of polarity group like piperazine could improve the solubility. Compound 23 was chosen to further evaluate anti-tumor efficacy in vivo. It showed higher inhibition rate and better safety than celastrol during in vivo experiment by intragastric administration. The preliminary antitumor studies of compound 23 in vivo showed that it might be promising for the development of new antitumor agents.

One-Pot Synthesis of O -Aryl Carbamates

A simple, versatile, one-pot procedure for the synthesis of substituted O-aryl carbamates has been developed, and a protocol is henceforth described. N-Substituted carbamoyl chloride is formed in situ and subsequently reacted with a substituted phenol, avoiding the direct manipulation of sensitive reactants. This procedure offers an economical and efficient route to many compounds of interest.